Smallpox drugmakers get new orders as monkeypox spreads –

Two samples of suspected cases of monkeypox go through a process of nucleic acid extraction as they get tested at a microbiology lab at La Paz Hospital in Madrid, Spain, June 1, 2022. REUTERS/Susana Vera
June 23 (Reuters) – Smallpox medicine makers Siga Technologies (SIGA.O) and Chimerix Inc (CMRX.O) said on Thursday they had received new orders for their antiviral drugs that are expected to be used as monkeypox treatments amid a global rise in infections.
More than 3,000 confirmed cases of monkeypox – which belongs to the family of orthopoxvirus that includes smallpox and cowpox – have been reported from 40 countries where the disease is not endemic. read more
With the numbers rising, the World Health Organization is set to decide on Thursday whether to declare monkeypox a global health emergency. read more
Siga received orders worth about $13 million for its oral smallpox drug, Tpoxx, and Chimerix got an order worth $9.3 million for its drug Tembexa.
Shares of Siga rose 4%, while Chimerix’s shares were up 5%.
Chimerix, which in May agreed to sell the rights of the drug to Emergent BioSolutions (EBS.N), said on Thursday the contract for new orders is expected to be completed before the sale goes through.
Siga’s drug, Tpoxx, is approved in the European Union to treat diseases including smallpox, monkeypox and cowpox, while it is only approved to treat smallpox in the United States and Canada.
"We expect a portion of the courses of oral Tpoxx delivered under these orders will be used for the treatment of active monkeypox cases," Siga Chief Executive Officer Phil Gomez said.
Our Standards: The Thomson Reuters Trust Principles.
The United States has already delivered more than 4 million doses of COVID-19 vaccines for children under 5 years old to sites that will administer the shots, a Department of Health and Human Services (HHS) spokesperson said on Thursday.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved


Leave a Reply

Your email address will not be published.